Figure 4-1. Overview of the analysis performed to select study design and transcriptomic platform specific dose response modeling parameters.

Figure 4-1Overview of the analysis performed to select study design and transcriptomic platform specific dose response modeling parameters

Subsets of data from two NTP datasets (Gwinn et al. 2020; https://doi.org/10.22427/NTP-DATA-002-00099-0001-000-1) were used in the analysis. Addressing the three goals outlined in the NTP report (i.e., increasing detection of true signal, minimizing false signal, and maximizing reproducibility) are denoted by the orange boxes.

From: 4, DEVELOPMENT OF TRANSCRIPTOMIC POINTS OF DEPARTURE FOR ETAP

Cover of Scientific Studies Supporting Development of Transcriptomic Points of Departure for EPA Transcriptomic Assessment Products (ETAPs)
Scientific Studies Supporting Development of Transcriptomic Points of Departure for EPA Transcriptomic Assessment Products (ETAPs).
Auerbach S, Casey W, Chang D, et al.
Washington (DC): U.S. Environmental Protection Agency; 2024 Mar.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.